Cardiovascular Simulation, Inc.
Cardiovascular Simulation, Inc. is listed today as Heartflow, Inc.: market value, financials and filings are on its company page.
Funding rounds
6 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2019 | $65 M | No. 6 | $50 to $250 million | equity | SEC | |
| Nov 2017 | $90 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jan 2015 | $100 M | No. 4 | $50 to $250 million | equity | SEC | |
| Dec 2011 | $105 M | No. 3 | $50 to $250 million | equity | SEC | |
| Aug 2010 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2010 | $2 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cardiovascular Simulation, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).
SEC Form D · Jun 2019
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jun 2019
That is all the official record says: Cardiovascular Simulation, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cardiovascular Simulation, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Bain Capital Life Sciences III General Partner, LLC | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Bain Capital Life Sciences Investors, LLC | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| BCLS Fund III Investments GP, LLC | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| BCLS Fund III Investments, LP | Fund or asset manager | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Hcpciv 1, LLC | Other | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners Fund LP | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners GP, LLC | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners II, L.P. | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners LP | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| HealthCor Partners Management LP | Fund or asset manager | not stated | not stated | Held Series C, D, E, F and F-1 preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| William C. Weldon | Person | not stated | not stated | Held Series D, F and F-1 preferred stock, director (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 29 investors.
Largest shareholders today
Institutions holding Heartflow, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$301 M6.87%
- Wellington Management Group LLP$276 M6.31%
- FMR LLC$273 M6.25%
- Bain Capital Life Sciences Investors, LLC$221 M5.06%
- Vanguard Portfolio Management LLC$185 M4.23%
- Vanguard Capital Management LLC$165 M3.77%
- Invesco Ltd.$134 M3.06%
- Bamco Inc /ny/$125 M2.86%
- D. E. Shaw & Co., Inc.$105 M2.40%
- Janus Henderson Group Ltd.$97 M2.21%
- Geode Capital Management, LLC$90 M2.07%
- State Street Corp$86 M1.97%
- Alliancebernstein L.P.$84 M1.91%
- Summit Partners Public Asset Management, LLC$72 M1.65%
- Morgan Stanley$71 M1.63%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Charles A. Taylor | Executive officer | Jun 2019 |
| Dana Mead | Executive officer | Jun 2019 |
| H. Baird A. Radford, III | Executive officer | Jun 2019 |
| Noemi C. Espinosa | Executive officer | Jun 2019 |
| Christopher K. Zarins | Executive officer | Dec 2017 |
| H. Baird M. Radford, Iii | Executive officer | Dec 2017 |
| John Stevens | Executive officer | Dec 2017 |
| Noemi C. Espinoza | Executive officer | Dec 2017 |
| H. Baird M. Radford, III | Executive officer | May 2016 |
| Nicky Espinosa Hayes | Executive officer | May 2016 |
| Casey A. Tansey | Director | Jun 2019 |
| Charles A. Taylor | Director | Jun 2019 |
| Dana Mead | Director | Jun 2019 |
| Jeff C. Lightcap | Director | Jun 2019 |
| John A. Stevens | Director | Jun 2019 |
| Kent A. Walker | Director | Jun 2019 |
| Lonnie A. Smith | Director | Jun 2019 |
| William A. Weldon | Director | Jun 2019 |
| Barry M. Uphoff | Director | Dec 2017 |
| Casey K. Tansey | Director | Dec 2017 |
| Christopher K. Zarins | Director | Dec 2017 |
| Jeff M. Lightcap | Director | Dec 2017 |
| John Stevens | Director | Dec 2017 |
| Kent M. Walker | Director | Dec 2017 |
| Lonnie M. Smith | Director | Dec 2017 |
| Philip M. Young | Director | Dec 2017 |
| Tom M. Hawes | Director | Dec 2017 |
| William M. Weldon | Director | Dec 2017 |
| Kent Espinosa Walker | Director | May 2016 |
| Barry A. Uphoff | Director | Feb 2014 |
| Casey Tansey | Director | Feb 2014 |
| Jesse K. Du Bey | Director | Feb 2014 |
| Lonnie C. Smith | Director | Feb 2014 |
| Thomas C. Hawes | Director | Feb 2014 |
| Eran K. Broshy | Director | Feb 2012 |
| Christopher K. Zarins, M.D. | Director | Apr 2010 |
| Robert Mitchell | Director | Apr 2010 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.